ADACEL

Indications

• Prevention of diphtheria through vaccination
• Treatment of diphtheria infection
• Management of respiratory obstruction due to pseudomembrane

Dosage

Children: Refer to specific

Adults: Refer to specific guidelines for the treatment of diphtheria. Antitoxin and antibiotics are typically used in treatment.

Mechanism of action

The pathogenicity of Corynebacterium diphtheriae is largely due to its production of diphtheria toxin, an A-B toxin that inhibits protein synthesis in host cells. The toxin is composed of two subunits: the A subunit, which enters the cytoplasm of the cell and catalyzes the ADP-ribosylation of elongation factor 2 (EF-2), leading to cell death, and the B subunit, which binds to the cell surface receptor, facilitating the entry of the A subunit. This results in local tissue damage and systemic effects, including myocarditis and neuropathy.

Pharmacodynamics

Diphtheria toxin exerts its effects primarily through inhibiting protein synthesis, causing cell death in susceptible tissues. The resulting necrosis can lead to the characteristic pseudomembrane formation in the throat and can affect other organs, including the heart and nervous system. The immune response to the toxin and the bacteria provides some level of protection, which is the basis for vaccination strategies.

Pharmacokinetics

The pharmacokinetics of the diphtheria toxin itself are not typically described in terms of absorption, distribution, metabolism, and excretion, as it is a potent toxin rather than a conventional drug. However, the body’s immune response to the toxin is crucial for recovery. After vaccination, the body generates antibodies against the toxin, which can neutralize its effects upon exposure to the bacterium.

Pregnancy

Diphtheria vaccination is recommended during pregnancy to protect the mother and fetus. The vaccine is inactivated and poses no risk.

Breast-feeding

Diphtheria vaccination is safe during breastfeeding. Antibodies may be transferred to the infant through breast milk.

Storage

Store in a refrigerator at 2-8 degrees Celsius. Do not freeze.

Formulations

• Diphtheria toxoid vaccine

Dosage

Children: Refer to specific clinical guidelines and BNF for Children for dosing information.

Adults: Refer to specific clinical guidelines and BNF for dosing information.

Mechanism of action

The mechanism of action for filamentous agents can vary widely but generally involves the inhibition of cell wall synthesis, disruption of cell membrane integrity, or interference with nucleic acid synthesis. For example, in the case of certain filamentous fungi, agents may target ergosterol synthesis, a key component of fungal cell membranes, leading to cell lysis and death.

Pharmacodynamics

Pharmacodynamics of filamentous agents typically includes the assessment of their effects on target microorganisms, including bactericidal or bacteriostatic activity. These agents may exhibit time-dependent or concentration-dependent killing, influencing the choice of dosing regimens. Their efficacy can be influenced by factors such as the growth phase of the microorganism, the presence of biofilms, and the ability of the agent to penetrate tissues.

Pharmacokinetics

The pharmacokinetics of filamentous agents vary based on their chemical structure and route of administration. Common parameters include absorption, distribution, metabolism, and excretion. Many filamentous agents are administered intravenously due to poor oral bioavailability. They may also have a large volume of distribution, indicating extensive tissue binding. Metabolism can occur in the liver, and renal excretion is common, necessitating dose adjustments in patients with renal impairment.

Pregnancy

Safety during pregnancy has not been established. Consult a healthcare provider.

Breast-feeding

Consult a healthcare provider before use while breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Bacterial infections
• Urinary tract infections
• Gastrointestinal infections
• Respiratory infections

Dosage

Children: Refer to relevant clinical guidelines for specific dosing information based on the type of bacterial infection.

Adults: Refer to relevant clinical guidelines for specific dosing information based on the type of bacterial infection.

Mechanism of action

Fimbriae mediate adhesion by interacting with specific receptors on host cells. This interaction facilitates the adherence of bacteria to epithelial surfaces, which is a critical step in the establishment of infection. Some fimbriae can also contribute to the formation of biofilms, enhancing bacterial survival in hostile environments.

Pharmacodynamics

The pharmacodynamics of fimbriae relate primarily to their ability to enhance bacterial adherence and colonization. By facilitating the attachment of bacteria to host tissues, fimbriae increase the likelihood of infection and can influence the severity and persistence of bacterial diseases.

Pharmacokinetics

As fimbriae are structural components of bacterial cells, they do not have a pharmacokinetic profile like conventional drugs. Instead, their presence and expression can vary among different bacterial species and strains, affecting their pathogenicity and the clinical outcomes of infections.

Pregnancy

Data on the use of fimbriae during pregnancy is limited. Consultation with a healthcare provider is recommended.

Breast-feeding

Limited data is available regarding the effects of fimbriae during breastfeeding. Consultation with a healthcare provider is recommended.

Storage

Store in a cool, dry place away from direct sunlight and moisture.

Indications

• Influenza prevention
• Influenza treatment
• Vaccine development for influenza

Dosage

Children: Refer to specific treatment guidelines for paediatric influenza management based on age and clinical presentation, as haemagglutinin is not administered as a standalone drug.

Adults: Refer to specific treatment guidelines for influenza based on clinical presentation and guidelines, as haemagglutinin is not administered as a standalone drug.

Mechanism of action

Haemagglutinin functions by specifically binding to sialic acid-containing receptors on the surface of host cells. This interaction triggers endocytosis of the virus, allowing it to enter the host cell. Once inside, the virus can release its genetic material, hijacking the host's cellular machinery to replicate and produce new viral particles. The specificity of haemagglutinin for different sialic acid variants influences the infectivity and host range of the virus.

Pharmacodynamics

The pharmacodynamics of haemagglutinin are closely tied to its role in viral pathogenesis. The strength and specificity of the binding between haemagglutinin and sialic acid receptors determine the virus's ability to infect specific tissues and initiate disease. Antibodies against haemagglutinin can neutralize the virus and are a key component of the immune response, which can lead to protective immunity following infection or vaccination.

Pharmacokinetics

As a component of a virus, haemagglutinin does not have pharmacokinetic parameters like absorption, distribution, metabolism, and excretion as traditional drugs do. Instead, its activity is related to the lifecycle of the virus it is part of. The degradation and clearance of haemagglutinin are dependent on the metabolism of the viral particles by the host's immune system and cellular mechanisms.

Pregnancy

Insufficient data available on the use of haemagglutinin during pregnancy. Consult healthcare providers for advice.

Breast-feeding

Data on the excretion of haemagglutinin in breast milk is not available. Caution is advised.

Storage

Store at 2-8°C. Protect from light and moisture.

Indications

• HER2-positive breast cancer
• Gastric cancer with HER2 overexpression
• Other malignancies that may express HER2

Dosage

Children: Paediatric dosing information is not available in the current data. Consult a pediatric pharmacology resource or the BNF for Children for guidance on dosing in children.

Adults: Dosage should be determined based on the specific indication and treatment regimen outlined in clinical guidelines. Refer to relevant treatment protocols for detailed dosing information.

Mechanism of action

Pertuactin binds specifically to the extracellular domain of the HER2 receptor. By doing so, it inhibits the signaling pathways associated with cell proliferation and survival that are activated by HER2. This binding can also flag the cancer cells for destruction by the immune system, enhancing the overall therapeutic effect.

Pharmacodynamics

The pharmacodynamic effects of pertuactin are primarily related to its ability to inhibit cell growth and induce apoptosis in HER2-positive cancer cells. This can lead to a reduction in tumor size and progression. The effectiveness of the drug may be influenced by the level of HER2 expression in the tumor, as well as other biological factors related to the cancer microenvironment.

Pharmacokinetics

Pertuactin demonstrates a complex pharmacokinetic profile that includes a long half-life due to its monoclonal antibody nature. It is generally administered intravenously, with distribution occurring across the vascular and interstitial compartments. The drug is metabolized by proteolytic degradation, and its elimination pathway is primarily through the reticuloendothelial system. The exact pharmacokinetic parameters such as clearance and volume of distribution can vary based on patient-specific factors, including body weight and overall health status.

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised as it is not known whether pertuactin is excreted in human milk. Weigh the potential benefits against the risks.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Indications

• Whooping cough (pertussis)
• Prevention of pertussis in infants and young children through vaccination

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Refer to the BNF for specific dosing information.

Mechanism of action

Pertussis toxin, produced by Bordetella pertussis, acts on host cells by ADP-ribosylating a G protein, which disrupts normal signal transduction pathways. This leads to increased production of cyclic AMP, inhibiting immune responses and contributing to the characteristic symptoms of the disease.

Pharmacodynamics

The clinical manifestations of pertussis are largely due to the immune response to the toxin and the bacterium itself. The disease progresses through stages: the catarrhal stage with mild symptoms, the paroxysmal stage with intense coughing fits, and the convalescent stage where symptoms gradually improve. The severity can vary, particularly in infants and young children, who are at higher risk for complications.

Pharmacokinetics

The pharmacokinetics of Bordetella pertussis are not typically described in the same manner as pharmaceutical agents. The organism does not have a traditional pharmacokinetic profile, but it primarily colonizes the ciliated epithelial cells of the upper respiratory tract. The immune clearance of the bacteria can take several weeks, depending on the host's immune response and treatment.

Adverse effects

• Cough
• Vomiting
• Fatigue
• Apnea (especially in infants)
• Weight loss
• Paroxysms of coughing
• Encephalopathy (rare)
• Pneumonia (secondary infection)

Precautions

• Use with caution in individuals with a history of seizures
• Consider potential for severe respiratory distress, especially in infants
• Monitor for complications, particularly in young children

Pregnancy

Pertussis vaccination is recommended during pregnancy to protect the newborn, especially during outbreaks.

Breast-feeding

Vaccination during breastfeeding is safe and can provide passive immunity to the infant.

Storage

Store in a cool, dry place away from direct sunlight. Follow specific storage instructions for vaccines.

Formulations

• DTaP vaccine (Diphtheria, Tetanus, and Pertussis)
• Tdap vaccine (Tetanus, Diphtheria, and Pertussis)

Indications

• Tetanus prophylaxis
• Treatment of tetanus infection
• Management of tetanus symptoms

Dosage

Children: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Adults: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Mechanism of action

The tetanus toxin binds to the presynaptic membrane of motor neurons and is transported retrogradely to the spinal cord, where it interferes with neurotransmitter release, particularly inhibiting the release of glycine and gamma-aminobutyric acid (GABA), leading to unopposed motor neuron activity and resultant muscle rigidity and spasms.

Pharmacodynamics

Tetanus toxin is one of the most potent toxins known, with effects that can manifest within hours of exposure. The toxin's ability to block inhibitory neurotransmitter release results in a state of continuous muscle contraction, known as tetany. The clinical presentation of tetanus includes trismus (lockjaw), muscle rigidity, and autonomic instability, among others.

Pharmacokinetics

The pharmacokinetics of tetanus toxin are complex due to its high potency and the nature of its action. Following entry into the body, the toxin binds to nerve endings and is internalized, leading to its effects on neurotransmitter release. The half-life of the toxin is not well defined as it does not circulate freely in the bloodstream but acts locally at the neuromuscular junction. Recovery from the effects of the toxin may take weeks to months, depending on the severity of the infection and the treatment provided.

Adverse effects

• Pain at the injection site
• Fever
• Fatigue
• Headache
• Nausea

Precautions

• Ensure patient is up to date with vaccinations
• Monitor for allergic reactions post-vaccination
• Consider history of neurological disorders

Pregnancy

Tetanus vaccination is considered safe during pregnancy and is recommended to protect both the mother and the newborn.

Breast-feeding

Tetanus vaccination is safe during breastfeeding and does not affect the nursing infant.

Storage

Store in a refrigerator at 2–8 degrees Celsius. Do not freeze.

Formulations

• Tetanus toxoid vaccine

Indications

• Diphtheria prophylaxis
• Tetanus prophylaxis
• Pertussis prophylaxis (when combined with other vaccines)

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for pediatric immunization with toxoids.

Adults: Refer to specific guidelines for each toxoid vaccine, as dosing may vary based on the type of vaccine and individual patient factors.

Mechanism of action

Toxoids work by stimulating the immune system to produce antibodies against the toxin without causing disease. When administered, the immune system recognizes the toxoid as a foreign substance and generates a specific immune response. This includes the production of immunoglobulin G (IgG) antibodies that can neutralize the active toxin if the individual is exposed to the bacteria in the future.

Pharmacodynamics

The pharmacodynamics of toxoids involve the activation of the adaptive immune response. After vaccination, dendritic cells present the antigen to T cells, which then help B cells differentiate into plasma cells that produce specific antibodies. The presence of these antibodies provides immunity against the toxin by neutralizing its effects, thereby preventing the disease associated with the original bacterial toxin.

Pharmacokinetics

Toxoids are typically administered via intramuscular or subcutaneous injection. Following administration, they are gradually taken up by antigen-presenting cells, which then process and present the toxoid to T cells. The immunogenic response can develop over several weeks. The duration of immunity can vary, necessitating booster doses to maintain adequate antibody levels over time.

Adverse effects

• Local reactions at the injection site, such as pain, swelling, or redness.
• Fever.
• Fatigue.
• Headache.
• Allergic reactions in rare cases.

Precautions

• Use with caution in individuals with a history of severe allergic reactions to a vaccine component.
• Monitor patients for allergic reactions post-vaccination.

Pregnancy

Toxoids are generally considered safe during pregnancy; however, consultation with a healthcare provider is recommended.

Breast-feeding

Toxoids are considered safe for use during breastfeeding.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Diphtheria toxoid
• Tetanus toxoid
• Pertussis toxoid

Dosage

Children: Refer to specific drug information for paediatric dosing guidance.

Adults: Refer to specific drug information for dosing guidance.

Mechanism of action

The mechanism of action for drugs classified under types varies widely depending on the specific drug. Generally, they may function by inhibiting specific enzymes, blocking receptors, or modulating biological pathways to achieve their therapeutic effects.

Pharmacodynamics

Pharmacodynamics for types of drugs varies significantly depending on the specific medication. In general, pharmacodynamics describes the relationship between drug concentration and effect, including the drug's efficacy, potency, and duration of action. Common dynamics include receptor binding, post-receptor effects, and the drug's influence on physiological functions.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of drugs within the body. For various types of drugs, absorption may occur via oral, intravenous, or other routes, distribution is influenced by protein binding and tissue permeability, metabolism typically occurs in the liver, and excretion occurs primarily via renal pathways. Specific parameters such as half-life, bioavailability, and clearance rates depend on the particular drug type.